FiercePharma3h
UPDATE: Merck KGaA sets its sights on acquisition of Ogsiveo maker SpringWorks
As SpringWorks Therapeutics nears a key regulatory decision in the U.S., the Connecticut-based cancer and rare disease ...
SpringWorks Therapeutics price target raised to $65 from $55 at BofA
BofA analyst Alec Stranahan raised the firm’s price target on SpringWorks Therapeutics (SWTX) to $65 from $55 and keeps a Buy rating on the ...
SpringWorks Therapeutics may be worth around $77 a share in a takeover - analyst
SpringWorks Therapeutics (SWTX) may be acquired by Merck KGaA for $77 per share, representing a potential premium of 92% ...
Why SpringWorks Therapeutics Inc. (SWTX) Soared on Monday
We recently compiled a list of the 10 Firms Begin Trading Week With Impressive Gains. In this article, we are going to take a ...
Springworks Therapeutics (SWTX) Gets a Buy from Barclays
Barclays analyst Peter Lawson maintained a Buy rating on Springworks Therapeutics (SWTX – Research Report) today and set a price target of ...
SpringWorks Therapeutics Shares Rise on Report it May be Acquired
SpringWorks Therapeutics shares rose 36% after Reuters reported Germany's Merck KGaA is in advanced talks to buy the company. Shares were trading around $54.66. The stock is up 16% over the last year ...
SpringWorks Stock Jumps More Than 30% on News of Possible Deal
Key Takeaways Shares of SpringWorks Therapeutics soared on Monday following a report that German medical firm Merck KGaA ...